open access
Intraperitoneal administration of radiolabelled monoclonal antibody pemtumomab (Yttrium-90-HMFG1) in gastric cancer
open access
Abstract
Aim
To evaluate the feasibility of treatment method (intraperitoneal administration of radiolabelled monoclonal antibody) for patients with gastric cancer.
Method
A total of 15 eligible patients, with histologically proven adenocarcinoma of the stomach or gastro-oesophageal junction, who had undergone resection to remove the primary tumour mass, were enrolled in the study. Eight patients were treated with the study drug and 7 of patients were enrolled into the standard care control arm.
Materials and Results
Mean blood radioactivity peaked between 36 and 48 hours, with a mean peak value of approximately 15% ID. Data previously reported on intraperitoneal Y-HMFG1 treatment of patients with ovarian cancer show peak values of 25 – 35% ID seen at 48 hour post-injection. The present results require confirmation in a large population of gastric cancer patients, but suggest that the transfer of radioactivity into the blood pool is decreased compared with the ovarian cancer patients.
Conclusions
A HAMA response was detected in all patients after treatment, and there is some suggestion that is follows a bi-phasic pattern. If as hypothesised, a HAMA response provides a boost to the immune system, leading to a potential longer term benefit, then the HAMA response seen in this study following pemtumomab treatment is encouraging.
Abstract
Aim
To evaluate the feasibility of treatment method (intraperitoneal administration of radiolabelled monoclonal antibody) for patients with gastric cancer.
Method
A total of 15 eligible patients, with histologically proven adenocarcinoma of the stomach or gastro-oesophageal junction, who had undergone resection to remove the primary tumour mass, were enrolled in the study. Eight patients were treated with the study drug and 7 of patients were enrolled into the standard care control arm.
Materials and Results
Mean blood radioactivity peaked between 36 and 48 hours, with a mean peak value of approximately 15% ID. Data previously reported on intraperitoneal Y-HMFG1 treatment of patients with ovarian cancer show peak values of 25 – 35% ID seen at 48 hour post-injection. The present results require confirmation in a large population of gastric cancer patients, but suggest that the transfer of radioactivity into the blood pool is decreased compared with the ovarian cancer patients.
Conclusions
A HAMA response was detected in all patients after treatment, and there is some suggestion that is follows a bi-phasic pattern. If as hypothesised, a HAMA response provides a boost to the immune system, leading to a potential longer term benefit, then the HAMA response seen in this study following pemtumomab treatment is encouraging.
Keywords
gastric cancer; intraperitoneal infusion; radiolabelled monoclonal antibody
About this articleTitle
Intraperitoneal administration of radiolabelled monoclonal antibody pemtumomab (Yttrium-90-HMFG1) in gastric cancer
Journal
Reports of Practical Oncology and Radiotherapy
Issue
Pages
49-56
Published online
2003-01-01
DOI
10.1016/S1507-1367(03)70994-8
Bibliographic record
Rep Pract Oncol Radiother 2003;8(2):49-56.
Keywords
gastric cancer
intraperitoneal infusion
radiolabelled monoclonal antibody
Authors
Paweł Murawa
Robert Kobylarek
Andrzej Gracz
Julian Malicki
Jerzy Kierzkowski